Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
NCT07388563Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of azacitidine and abatacept in T-cell lymphoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Complete Response Rate and Maximum Tolerated Dose at 56 days. Started Mar 2026; status: recruiting.
02
Drugs
azacitidineabatacept
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT07388563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388563.